Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial – Monday, March 24, 2025 – The webinar will be available soon
Open to access this content
